Please login to the form below

Not currently logged in

Lucid wins med ed consultancy award at Communiqué

It also sees success with a professional education programme for AbbVie
Lucid wins med ed consultancy award at Communiqué

The Lucid Group took home the Communiqué Medical Education Consultancy of the Year award at last night's Communiqué Awards 2015 - the third time in a row that it's won the category.

The agency last year opened new offices in London and New York, redeveloped its medical education offering, engaging with new partners and developing behaviour-change methodologies to change clinical practice and improve patient outcomes.

Commenting on this the Communiqué judges said: “Lucid were a clear winner with a very lucid proposition that showed how they had upped their game in 2014. 

“The agency demonstrated great integrity and what they're offering is tremendously powerful - and last year they took it to a new level. This is an agency with a very impressive mission that could be held up to the industry as a leader.”

Commenting on the win Jan Steele, Lucid's operations director, said: “As a specialist medical education agency, this is the award we always want to win and we are delighted to have done so for a third year running.

"We are passionate about our approach to medical education. We strive to be industry-leading thinkers. We utilise the latest academic thinking and evidence on the psychology of behaviour change and education interventions to build tailor-made programmes. We are driven in everything we do by our passion for advancing clinical practice and improving patient outcomes.

There was further success for Lucid in the Excellence in Professional Education Programmes category, where its Parkinson's disease programme PD communicate for AbbVie was a finalist, and its Treat to Target UK - also for AbbVie - won the award.

Treat to Target UK: A professional education programme to drive Treat to Target (T2T) implementation and improve outcomes for patients with rheumatoid arthritis (RA) across the UK aims to improve outcomes for patients with RA and prevent irreversible joint damage.

It saw Lucid collaborate with the UK T2T steering committee, led by Professor Paul Emery, and then design a behaviour-change programme to ensure disease activity is monitored routinely and used to inform patient outcomes.

Commenting on Lucid's work the Communiqué judges said: “This continues to be a very solid and engaging programme and it's clear that both the agency and the client know exactly what's required.

“It has become a real 'rock star' programme that we would have been proud to work on. The momentum is enormous and it continues to have fantastic longevity with genuine commitment for the future.”

Run by PMLiVE publisher the PMGroup, the Communiqué programme is specifically designed to recognise and commend excellence and best practice in local, European and international healthcare communications.

See the full results of the Communiqué Awards 2015

Article by
Dominic Tyer

3rd July 2015

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...